ATRX (Adhera Therapeutics) Total Payout Yield %: 0.00 (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATRX Adhera Therapeutics Inc ATRX
12 GF Score
Price $0.00
View Full Analysis

What is Adhera Therapeutics Total Payout Yield %?

Adhera Therapeutics ATRX 12 Total Payout Yield % is 0.00 as of Aug. 01, 2026. GuruFocus rates ATRX with a GF Score™ of 12/100.

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Adhera Therapeutics's current Total Payout Yield % is 0.00%.


Adhera Therapeutics Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.


Adhera Therapeutics Total Payout Yield % Related Terms


Adhera Therapeutics Total Payout Yield % Historical Data

* Premium members only.

The historical data trend for Adhera Therapeutics's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adhera Therapeutics Total Payout Yield % Chart

Adhera Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Payout Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.30 0.00 0.00 0.00 0.08

Adhera Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Payout Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ATRX vs PKBO, ARDS, NYMXF: Total Payout Yield % Comparison

For the Biotechnology subindustry, Adhera Therapeutics's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adhera Therapeutics Total Payout Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adhera Therapeutics's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Adhera Therapeutics's Total Payout Yield % falls into.


ATRX
12GF Score
Adhera Therapeutics Inc ATRX
Total Payout Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adhera Therapeutics Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Adhera Therapeutics's Total Payout Yield % for the fiscal year that ended in Dec. 2022 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Market Cap
=- (-0.002 + 0 + 0) / 2.59186195
=0.08%

Adhera Therapeutics's annualized Total Payout Yield % for the quarter that ended in Sep. 2023 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) * Annualized Factor / Market Cap
=- (0 + 0 + 0) * 4 / 0.15507
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Payout Yield % →
What does a Total Payout Yield % of 0.00 mean?
Adhera Therapeutics (ATRX) has a Total Payout Yield % of 0.00 as of Aug. 01, 2026. Total Payout Yield is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Market Cap. View historical data on Adhera Therapeutics and its competitors.
Is Adhera Therapeutics' Total Payout Yield % too high?
Adhera Therapeutics' current Total Payout Yield % is 0.00. Overall, Adhera Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Adhera Therapeutics' Total Payout Yield % compare to PKBO and ARDS?
Adhera Therapeutics' Total Payout Yield % of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Yield % for a Biotechnology company?
A good Total Payout Yield % depends on the Biotechnology industry context. However, Total Payout Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Yield % mean?
A high Total Payout Yield % can signal that a stock is expensive relative to its fundamentals. Total Payout Yield is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Market Cap. View historical data on Adhera Therapeutics and its competitors. Adhera Therapeutics's current Total Payout Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adhera Therapeutics stock overvalued right now?
Adhera Therapeutics (ATRX) has a current Total Payout Yield % of 0.00. The current Total Payout Yield % is 0.00. Adhera Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Yield % calculated?
Total Payout Yield % is calculated from a company's financial statements. For Adhera Therapeutics (ATRX), the current Total Payout Yield % is 0.00 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adhera Therapeutics Business Description

Address 8000 Innovation Parkway, Baton Rouge, LA, USA, 70820
Adhera Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing advanced drug candidates through accelerated pathways. The company's pipeline includes MLR-1019 for Parkinson's disease and MLR-1023 for diabetes, both licensed from the Melior Discovery group. MLR-1019 (armesocarb) is a drug candidate targeting both movement and non-movement symptoms of Parkinson's disease, while MLR-1023 (tolimidone) is being developed for Type 1 diabetes and has undergone Phase 2a and 2b studies in Type 2 diabetes patients. It also explores additional drug development opportunities and maintains legacy assets such as CEQ508, an oral RNA therapy candidate for polyps associated with Familial Adenomatous Polyposis (FAP).
12GF Score

Get the complete analysis for ATRX

Total Payout Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price